Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash Flows From Operating Activities    
Net loss $ (4,679,035) $ (2,583,433)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 6,334 6,334
Non-cash lease expense for right-of-use assets 59,875 55,012
Non-cash acquisition of in-process research and development 2,000,000
Amortization of debt issuance costs (Note 5) 157,129
Amortization of intangible asset 596,496 596,496
Deferred income tax benefit (286,421) (442,152)
Stock-based compensation 357,039 394,164
Net changes in operating assets and liabilities:    
Prepaid expenses and other 272,750 37,552
Operating lease liability (58,881) (58,999)
Accrued interest 67,802 8,587
Accounts payable 351,839 (227,241)
Due (from) to related parties 102,875 46,647
Accrued expenses 184,359 30,374
Net cash used in operating activities (867,839) (2,136,659)
Cash Flows From Financing Activities    
Proceeds received in satisfaction of stock subscription receivable 900,000
Borrowings on line of credit from a related party 700,000
Proceeds received from our Paycheck Protection Program note payable 162,459
Transaction costs related to subsequent common stock offering (360,728)
Net cash provided by financing activities 501,731 900,000
Net Decrease in Cash (366,108) (1,236,659)
Cash and Cash Equivalents - Beginning of Period 691,536 1,740,961
Cash and Cash Equivalents - End of Period 325,428 504,302
Non-Cash Investing and Financing Activities    
Right-of-use asset obtained in exchange for operating lease liability (293,198)
Reduction in deferred lease liability (9,963)
Operating lease liability 303,161
Net
Issuance of 250,000 shares of common stock for the acquisition of in-process research and development in connection with the Yuhan License Agreement 2,000,000
Issuance of 28,971 shares of common stock due to triggering, in December 2019, the full ratchet anti-dilution provision of common stock sold in our 2018 Private Placement Transactions $ 3